Thus, changes in Ccl2 and Ccr2 transcripts (Fig. 6) indicate that AC261066 could inhibit one of the early inflammatory responses involved in NAFLD/NASH development via RARβ in Kupffer cells. Here, CCR2 is linked to metabolic dysfunction-associated steatotic liver disease.